MUDr. Viera Sandecká, Ph.D.
Assistant professor, Department of Internal Medicine, Hematology and Oncology
phone: | +420 532 23 3881, 3603 |
---|---|
e‑mail: | Sandecka.Viera@fnbrno.cz |
social and academic networks: |
---|
Total number of publications: 110
2024
-
CIRCULATING TUMOR CELLS HAVE HIGH PROGNOSTIC SIGNIFICANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH PARASKELETAL OR EXTRAMEDULLARY PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Blood Cancer Journal, year: 2024, volume: 14, edition: 1, DOI
-
Del(1p32) is an early and high-risk event in relapsed multiple myeloma patients with extraosseous plasmacytomas
Year: 2024, type: Conference abstract
-
Dysregulation of microRNA in Waldenström macroglobulinemia
Year: 2024, type: Conference abstract
-
EFFICACY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE REGIMEN IN DARATUMUMAB-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE ANALYSIS
Year: 2024, type: Conference abstract
-
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
European Journal of Haematology, year: 2024, volume: 113, edition: 6, DOI
-
EL(1P32) IS AN EARLY AND HIGHRISK EVENT IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH EXTRAOSSEOUS PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Úspěšná léčba relapsu Waldenströmovy makroglobulinemie (WM) inhibitory proteazomu
Klinická onkologie, year: 2024, volume: 37, edition: 6, DOI
-
Úspěšná léčba relapsu Waldenströmovy makroglobulinemie inhibitory proteazomu (bortezomibem a následně ixazomibem) v kombinaci s rituximabem a dexametazonem. Popis případu a přehled přínosu inhibitorů proteazomu pro Waldenströmovu makroglobulinemii
Klinická onkologie, year: 2024, volume: 37, edition: 6, DOI
2022
-
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Neoplasma, year: 2022, volume: 69, edition: 5, DOI